Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Neurocrine Biosciences — FY2024 Earnings Presentation
40 slides from Neurocrine Biosciences's earnings presentation, Feb 6, 2025
Slide 1: Q4 and Year-End 2024 Earnings Presentation
Advancing Life-Changing Discoveries in Neuroscience Neurocrine Biosciences (Nasdaq: NBIX) Q4 and Year-End 2024 Earnings Presentation February 6, 2025
Slide 2: Safe Harbor and Forward-Looking Statements
Safe Harbor and Forward-Looking Statements In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products an
Slide 3: Where Are We Today?
Where Are We Today? Neurocrine Discovered / Developed Discovered and Developed Four Novel FDA-Approved Programs In the U.S. Deep Expertise in Neuroscience Drug Development * Fully-Integrated Organization with R&D and Commercial Capabilities Growing Blockbuster Commercial Product in INGREZZA with Str
Slide 4: Well-Positioned for Sustained & Long-Term Growth
Well-Positioned for Sustained & Long-Term Growth COMMERCIAL* RESEARCH & DEVELOPMENT STRONG FINANCIAL POSITION • Neurology $2.50 - $2.60 Billion • Neuroendocrinology Therapeutic 2025 INGREZZA Area Annual Net Sales Guidance • Neuropsychiatry TARDIVE DYSKINESIA AND Diversification HUNTINGTON’S DISEASE
Slide 5: Our Pipeline Today – 12 Programs
Modality Key Our Pipeline Today – 12 Programs Small Molecule PROGRAM (TARGET) MODALITY THERAPEUTIC AREA INDICATION PHASE 1 PHASE 2 PHASE 3 valbenazine (VMAT2 Inhibitor) Neuropsychiatry Adjunctive Treatment of Schizophrenia valbenazine (VMAT2 Inhibitor) Neurology Dyskinetic Cerebral Palsy Inadequate
Slide 6: 2024 Highlights and 2025 Key Milestones and Activities
2024 Highlights and 2025 Key Milestones and Activities 2024 Highlights 2025 Key Milestones and Activities ▪ INGREZZA® (valbenazine) Net Product Sales of ~$2.31B in 2024 ▪ Deliver on INGREZZA Net Sales Guidance of $2.5 - $2.6B − Represents ~$480 Million YoY Sales Growth, or 26% vs. 2023 ▪ Successfull
Slide 7: 2024 Financial Summary
2024 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item 2024 2023 Highlights / Comments Revenue $2,355 $1,887 2024 INGREZZA Sales of ~$2.3B Represents YoY Growth of - Product Sales, Net $2,331 $1,861 26% vs. FY 2023 - Collaboration Revenue $25 $27 Increase Due to Support Expanded
Slide 8: Q4 2024 Financial Summary
Q4 2024 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q4 2024 Q4 2023 Highlights / Comments Revenue $628 $515 INGREZZA Sales of $615M Represents YoY Growth of 23% - Product Sales, Net $621 $507 Driven by Strong Underlying Patient Demand and Improvement in Gross-to-Net Dynamic
Slide 9: 2025 INGREZZA Net Sales and Expense Guidance
2025 INGREZZA Net Sales and Expense Guidance Item ($ Millions) 2024 Actuals 2025 Guidance Range INGREZZA Net Product Sales1 $2,314 $2,500 - $2,600 GAAP R&D Expense2 $731 $960 - $1,010 Non-GAAP R&D Expense2, 3 $662 $890 - $940 GAAP SG&A Expense4 $1,007 $1,110 - $1,130 Non-GAAP SG&A Expense3, 4 $863 $
Slide 10: Corporate Sustainability: "A" Rating at MSCI
Corporate Sustainability: “A” Rating at MSCI and Rank in 11th Percentile for Biotech at Sustainalytics Our Purpose: Relieve Suffering for People with Great Needs Adhere to the highest Invest in our people Minimize our impact product quality and and communities on the environment safety standards Com
Slide 11: Our Medicines, Our Patients
© NEYROCRINE | Our Medicines, Our Patients
Slide 12: INGREZZA (valbenazine) capsules
NEUROGRINE INGREZZA (valbenazine) capsules
Slide 13: INGREZZA Quarterly Net Sales Performance
INGREZZA Quarterly Net Sales Performance ($Million) Q4 2024 Sales of $615M Represents $650 23% Year-Over-Year Growth vs. Q4 2023 $613 $615 $600 $580 $550 $500 $506 $500 $486 $450 $440 $410 $400 $350 Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 13
Slide 14: Substantial Impact on TD Patients and Care Partners
Substantial Impact on TD Patients and Care Partners Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Wo
Slide 15: Nascent Tardive Dyskinesia Market Presents Significant Opportunity
Nascent Tardive Dyskinesia Market Presents Significant Opportunity ESTIMATED TO AFFECT ~800,000 Nearly 9 of 10 TD PATIENTS ARE NOT CURRENTLY people in the U.S. TREATED WITH A VMAT2 INHIBITOR LIKE INGREZZA Source: U.S.Claims Data and 31 Global Scientific Publications; U.S. Tardive Dyskinesia Prevalen
Slide 16: INGREZZA Approved by the FDA for Chorea Associated with Huntington's Disease
INGREZZA® Approved by the FDA for the Treatment of Chorea Associated with Huntington’s Disease INGREZZA Simple once-a-day treatment targeted for symptom control of chorea movements Safety profile consistent with and supported by extensive safety data in tardive dyskinesia In randomized, double-blind
Slide 17: CRENESSITY
mn yd Crenessity™ PeNeoolty NEUROCRINE’ BIOSCIENCES
Slide 18: CRENESSITY Offers Potential to Change Standard of Care
CRENESSITY Offers Potential to Change Standard of Care First New Treatment Available for Classic CAH in 70 Years ABOUT CRENESSITY ABOUT CAH • First medication approved as an adjunct treatment to • Rare and lifelong genetic condition that affects glucocorticoid replacement to control androgens in app
Slide 19: Neuropsychiatry Pipeline
(5) NEUROCRINE BIOSCIENCES
Slide 20: Osavampator: Positive Phase 2 Top-Line Results in Major Depressive Disorder
Osavampator* (AMPA Potentiator): Reported Positive Phase 2 Top- Line Study Results in Adults with Major Depressive Disorder Inadequate Response to Treatment osavampator (previously NBI-’845) in Major Depressive Disorder (MDD) Potent first-in-class AMPA potentiator ~1/3 of the 16 million+ people in t
Slide 21: Osavampator SAVITRI Phase 2 Summary Results
TM Osavampator* (AMPA Potentiator) SAVITRI Phase 2 Study Summary Results EFFICACY SAFETY AND TOLERABILITY • The study met its primary and key secondary endpoints • NBI-1065845 was generally well-tolerated • Once-daily, oral administration of NBI-’845 produced a • Most common adverse event was headac
Slide 22: Muscarinic Platform Includes Multiple Clinical Programs
Muscarinic Platform Includes Multiple Clinical Programs From M1 to M4 Selective Orthosteric Agonists M1 M1/M4 M4 “Cognition” DUAL “Psychosis” ▪ Phase 1 PREFERRING ▪ Advancing to Phase 2 in PREFERRING Schizophrenia in 2H 2025 ▪ Phase 1 ▪ Phase 1 NBI-’570 SELECTIVE NBI-’567 NBI-’569 SELECTIVE ▪ Comple
Slide 23: Summary of NBI-'568 Positive Phase 2 Topline Results
Summary of NBI-’568* Positive Phase 2 Topline Results Once-Daily 20mg Dose: Efficacy, Safety, and Tolerability Results Support Advancement to Phase 3 in 1H 2025 20mg Once-daily Demonstrated Efficacy, Safety and Tolerability Profile Statistically Significant and Clinically Generally Safe and Well-tol
Slide 24: PANSS Total Score Change from Baseline
Once-Daily 20mg Dose Demonstrated Clinically Meaningful and Statistically Significant Efficacy at Week 3, 4, 5, and 6 0 20mg QD Efficacy Data PANSS Total Score Change from Baseline LS Mean1 ± SEM -5.7 Week 4 – Week 6 -5 -8.2 -7.7 Week 4 5 6** -9.6 PANSS Total Score -8.4 -10.2 -10 -10.8 -11.5 LS Mean
Slide 25: Statistically Significant Improvement in Additional Endpoints
Once-Daily 20mg Dose Demonstrated Statistically Significant Improvement in Additional Endpoints \ CGI-S Marder Factor — Positive Marder Factor — Negative Placebo 20mg QD Placebo 20mg QD Placebo 20mg QD Week 6 N=68 N=35 N=68 N=35 N=68 N=35 LS Mean Change from Baseline* -0.5 -1.2 -2.8 -5.8 -1.2 -3.1 L
Slide 26: NBI-'568 Was Generally Safe and Well Tolerated at All Doses Studied
NBI-’568 Was Generally Safe and Well Tolerated at All Doses Studied Treatment-Emergent Adverse Events Occurring in ≥ 5% of NBI-'568 All Treated Group Placebo 20mg QD 40mg QD 60mg QD 30mg BID All Treated \ N=70 N=40 N=39 N=34 N=27 N=140 Somnolence 2 (2.9) 5 (12.5) 2 (5.1) 7 (20.6) 1 (3.7) 15 (10.7) D
Slide 27: NBI-'568 is the First and Only Muscarinic M4 Selective Orthosteric Agonist
NBI-’568 is the First and Only Muscarinic M4 Selective Orthosteric Agonist in Clinical Development Type of Large Opportunity For NBI-'568, A Novel And Subtype Requires Endogenous Muscarinic Differentiated Asset Selectivity Ligand (Acetylcholine) Activation With no reliance on innate acetylcholine le
Slide 28: NBI-'568 Effect Size Comparable to Known Muscarinic Programs
NBI-’568 Effect Size Comparable to Known Muscarinic Programs and Leading Antipsychotics Clinical-Stage Muscarinic Programs Leading Approved Treatments 0.75 0.68 0.61 0.61 0.60 Effect Size 0.56 0.55 0.42 0.41 0.36 0.34 0.3 0.26 125mg / 30mg 30mg QD 125mg / 30mg 20mg 125mg / 30mg Zyprexa Risperdal Ser
Slide 29: Valbenazine Phase 3 Study for Adjunctive Treatment of Schizophrenia
Valbenazine*: Phase 3 Study for the Adjunctive Treatment of Schizophrenia with Top-Line Data in 2025 Adjunctive Treatment of Schizophrenia (ATS) Schizophrenia is one of the leading causes of disability worldwide, affecting up to 3.5M people in the U.S. alone. A serious, chronic mental illness that c
Slide 30: Neurology Pipeline
© NEVROGRINE Neurology Pipeline
Slide 31: Neurology Programs in Clinical Development
Neurology Programs in Clinical Development Valbenazine* Valbenazine in ATS NBI-’890* RESEARCH & DEVELOPMENT NBI-’355* POSITION STRONG FINANCIAL • VMAT2 Inhibitor • Next Generation VMAT2 Inhibitor • Selective Nav1.2 / Nav1.6 Inhibitor • Ongoing Phase 3 Study in Dyskinetic ✓ High Potency / Low Solubil
Slide 32: R&D Will Deliver A New Medicine Every Two Years
R&D Will Deliver A New Medicine Every Two Years Multimodality Mid-stage pipeline focused on clinically Commitment to R&D innovation engine or genetically validated targets R&D Sustainability Research 4+ Phase 1 Starts Target level of productivity each year 2+ Phase 2 Starts (On Average) 3+ Phase 3 P
Slide 33: Our Pipeline Tomorrow – 18 Programs
Modality Key Small Molecule Peptide Antibody Gene Therapy Our Pipeline Tomorrow – 18 Programs Study Status Key End of 2025 Current Study Study Initiating PROGRAM (TARGET) MO D A L I T Y THERAPEUTIC AREA INDICAT I ON PHASE 1 PHASE 2 PHASE 3 valbenazine (VMAT2 Inhibitor) Neuropsychiatry Adjunctive Tre
Slide 34: Well-Positioned for Sustained & Long-Term Growth
Well-Positioned for Sustained & Long-Term Growth COMMERCIAL* RESEARCH & DEVELOPMENT STRONG FINANCIAL POSITION • Neurology $2.50 - $2.60 Billion • Neuroendocrinology Therapeutic 2025 INGREZZA Area Annual Net Sales Guidance • Neuropsychiatry TARDIVE DYSKINESIA AND Diversification HUNTINGTON’S DISEASE
Slide 35: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations
Slide 36: Condensed Consolidated Statements of Income
NEUROCRINE’ BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in millions, except per share data) Revenues: Net product sales Collaboration revenue Total revenues Operating expenses: Cost of revenues Research and development Acquired in-process research and develo
Slide 37: Condensed Consolidated Balance Sheets
NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) December 31, December 31, (in millions) 2024 2023 Cash, cash equivalents, and marketable securities $ 1,076.1 $ 1,031.6 Other current assets 648.6 575.4 Total current assets 1,724.7 1,607.0 Deferred tax assets 485.7 362.6
Slide 38: Reconciliation of GAAP to Non-GAAP Financial Results
NEUROCRINE’ BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS, (unaudited) Three Months Ended ‘Twelve Months Ended December 31, December 31, (in millions, except per share data) 2024 2023 2024 2023 GAAP net income ! $ 103.1 $ 147.7 $ 3413 $ 249.7 Adjustmen
Slide 39: Reconciliation of GAAP to Non-GAAP Expenses
NEUROCRINE’ BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (unaudited) (n mitions) GAAP cost of revenues Adjustments: Non-cash amortization related to acquired intangible assets ‘Non-GAAP cost of revenues (in miions) GAAP R&D Adjustments Stock-based compensation
Slide 40: Advancing Life-Changing Discoveries in Neuroscience
Advancing Life-Changing Discoveries in Neuroscience Neurocrine Biosciences (Nasdaq: NBIX) Q4 and Year-End 2024 Earnings Presentation February 6, 2025
Neurocrine Biosciences — FY2024 Earnings Presentation on 6ix